Futibatinib: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Futibatinib: clinical details
Prescribing considerations
- Confirm an FGFR2 fusion or rearrangement using an appropriate diagnostic test.
- Treatment should be initiated by a clinician experienced in biliary tract cancer.
- Review CYP3A inhibitors and inducers before prescribing.
- Consider the limited evidence in severe renal impairment, dialysis and severe hepatic impairment.
- Use particular caution with clinically significant retinal disease.
- The product has conditional approval and is subject to additional monitoring.
Contraindications and cautions
- Hypersensitivity to futibatinib or any excipient.
- The formulation should not be used in rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
Monitoring
- Monitor serum phosphate and manage persistent elevation to reduce the risk of soft-tissue mineralisation.
- Arrange an ophthalmological examination before treatment and further eye monitoring; obtain urgent assessment for visual symptoms.
- Perform pregnancy testing before initiation when relevant.
- Monitor clinically for gastrointestinal, nail, skin, oral, ocular and hepatic adverse effects.
Clinical pharmacology
Futibatinib is an irreversible covalent inhibitor of FGFR1–4. It is predominantly cleared through CYP3A-mediated metabolism and glutathione conjugation; FGFR inhibition causes the characteristic rise in serum phosphate.
Formulation and product differences
- The selected product is a round, white film-coated tablet intended to be swallowed whole.
- It contains lactose and is essentially sodium-free.
- Wallet configurations contain different tablet quantities; patients should follow their specific pack instructions.
Futibatinib preparations and strengths
Tablet
Route: Oral
Strengths: 4 mg
Futibatinib interactions
The oncology team should review all prescribed, over-the-counter and herbal products before and during treatment.
Strong CYP3A inhibitors, including itraconazole and clarithromycin
May increase futibatinib exposure and toxicity; combined use should usually be avoided.
Strong or moderate CYP3A inducers, including rifampicin, carbamazepine, phenytoin, phenobarbital and efavirenz
May lower futibatinib exposure and reduce its activity; combined use should usually be avoided.
Theophylline and olanzapine
Futibatinib may reduce their exposure through CYP1A2 induction, potentially reducing their effect.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.